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Breast cancer is the most commonly occurring cancer
among women. The disease frequently attacks women at
a young age. The German population has been greatly
affected by breast cancer with approximately 74,500
females and 600 males being diagnosed with the disease
in 2012 alone. In many instances the cause of breast
cancer is unknown. Genetic factors that greatly contri-
bute to breast cancer are mutations of both BRCA1 and
BRCA2 genes. These occur in 10% of patients. Little is
known so far about the contribution of other genes to
the occurrence of breast cancer.
Here we report the mutation spectrum in genes that
increase the risk of familial breast cancer in patients
seeking genetic counseling in our Institute. The patients
come from the region of Saxony in Germany, close to
the Polish and Czech borders. Altogether we performed
mutation analysis in 325 patients: 17 males and 308
females; deriving from a total of 216 families with breast
and ovarian carcinoma.
All individuals were screened for mutations in six
breast cancer susceptibility genes: BRCA1, BRCA2,
CHEK2, PALB2, RAD51, and RAD51C. In the case of
negative results and special family history we also ana-
lyzed other genes: p53, ATM, PTEN, NBS1, NOD2,
STK11, and CDH1. BRCA 1/2 were analyzed by multi-
plex-ligation-dependent probe-amplification (MLPA),
PCR, and direct sequencing (including intron/exon
boundaries). Other genes were analyzed by PCR and
direct sequencing including intron/exon boundaries.
We observed BRCA1 gene mutations in 15% of families
(10% pathogenic and 5% unclassified variants). Three
mutations were novel and not described. Of the BRCA2
gene mutations we identified in 35% of families (12%
pathogenic and 23% unclassified variant), 5 were not
described before. In three families we found large geno-
mic rearrangements in BRCA1/2 by MLPA method. The
PALB2 gene mutations occurred in 8% of our probants,
and the CHEK2 mutation were observed in 4% of
families. In 10% of families sequence variants in others
analyzed genes were noted.
The total number of pathogenic mutations in our
group of patients is compatible with the result from the
German Familial Breast Cancer Consortium reporting
30% of mutations in BRCA1 and BRCA2 of families with
a family history of breast cancer. However the spectrum
of mutations is somehow different with more mutations
in BRCA2 and CHEK2 as well as PALB2. Particularly for
CHEK2 we found a higher rate of pathogenic mutation [1].
This suggests that a screening spectrum of genes for
familial breast cancer needs to be adjusted to the regional
specification.
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